An impurity is defined by the United States Pharmacopeial (USP) as “any component of a drug substance that is not the chemical entity defined as the drug substance” and a drug product impurity is “any component that is not a formulation ingredient”. Impurities in an active pharmaceutical ingredient (API) or drug product may arise as a result of synthetic/manufacturing processes, degradation, storage conditions, containers, excipients, or contamination. According to the definitions of International Council for Harmonization (ICH), Food and Drug Administration (FDA), and USP, impurities are classified into degradation-related impurities (DRIs), process-related impurities (PRIs), residual solvents, and heavy metals.

Regardless of the type of impurity, the presence of an impurity may affect the quality, safety, and efficacy of a drug product. API-related impurities are potentially genotoxic, mutagenic, and carcinogenic due to their structure-activity relationship (SRA). In API-related impurities, one type is the impurities generated by degradation of API itself under specific storage conditions, such as oxidation, dehydration, carbon dioxide removal. The other type is generated due to the interaction between APIs and excipients, container, or residual impurities in excipients, reagents, or solvents. Excipients or the residual impurities in excipients (such as active peroxides or high-water content in povidone or polyethylene glycol (PEG), antioxidants in magnesium stearate, benzaldehyde in benzyl alcohol) are likely to lead to instability of APIs and pharmaceutical products. In addition, initiators/catalysts, storage stabilizers, antioxidants, processing aids, light stabilizers, etc., may also pose uncertain risks to the stability or quality of products.

One of the keys to the development of APIs and manufacturing process is the determination of a drug substance impurity profile. Analytical monitoring and controlling of impurities is often challenging and is conducted under the regulatory requirements. The exact identification and quantification of impurities in pharmaceuticals is essential for documentation of registration of pharmaceutical products, and impurity reference standards play a vital role. Amerigo Scientific provides more than 1,000 impurity reference standards for drug development and API manufacturing.

Products (1176)
Sort by: Cat. No.
Show (10) per page
AA145165
  • Size:
  • Catalog Number: I003183463BIO
AA64743
  • Size:
  • Catalog Number: I003184168BIO
AC61620
  • Size:
  • Catalog Number: I003183232BIO
AD21086
  • Size:
  • Catalog Number: I003183370BIO
AG46304
  • Size: 1 mg
  • Catalog Number: I003183814BIO
BC165848
  • Catalog Number: I003183215BIO
FA146003
  • Size:
  • Catalog Number: I003183810BIO
FA156914
  • Size:
  • Catalog Number: I003183681BIO
FA161770
  • Size:
  • Catalog Number: I003184190BIO
FA165520
  • Size: 20 mg
  • Catalog Number: I003183888BIO

Online Inquiry

Contact Us

Copyright © Amerigo Scientific. All rights reserved.